Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review

被引:333
作者
Malet-Martino, M [1 ]
Martino, R [1 ]
机构
[1] Univ Toulouse 3, Grp RMN Biomed, Lab IMRCP, CNRS,UMR 5623, F-31062 Toulouse, France
关键词
Xeloda((R)); Orzel (TM); TS-1; toxicity; phase I; II; III trials;
D O I
10.1634/theoncologist.7-4-288
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although 5-fluorouracil (5-FU) was first introduced in 1957, it remains an essential part of the treatment of a wide range of solid tumors. 5-FU has antitumor activity against epithelial malignancies arising in the gastrointestinal tract and breast as well as the head and neck, with single-agent response rates of only 10%-30%. Although 5-FU is still the most widely prescribed agent for the treatment of colorectal cancer, less than one-third of patients achieve objective responses. Recent research has focused on the biomodulation of 5-FU to improve the cytotoxicity and therapeutic effectiveness of this drug in the treatment of advanced disease. As all the anticancer agents, 5-FU leads to several toxicities. The toxicity profile of 5-FU is schedule dependent. Myelotoxicity is the major toxic effect in patients receiving bolus doses. Hand-foot syndrome (palmar-plantar erythrodysesthesia), stomatitis, and neuro- and cardiotoxicities are associated with continuous infusions. Other adverse effects associated with both bolus-dose and continuous-infusion regimens include nausea and vomiting, diarrhea, alopecia, and dermatitis. All these reasons explain the need for more effective and less toxic fluoropyrimidines. In the first part of this review, we briefly present the metabolic pathways of 5-FU responsible for the efficacy and toxicity of this drug. This knowledge is also necessary to understand the target(s) of biomodulation. The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, ie., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). The pharmacological principles that have influenced the development of these new drugs and our current knowledge of the clinical pharmacology of these new agents, focusing on antitumor activity and toxicity, are presented. The literature was analyzed until March 2002. This review is intended to be as exhaustive as possible since it was conceived as a work tool for readers wanting to go further.
引用
收藏
页码:288 / 323
页数:36
相关论文
共 335 条
[51]   METABOLISM OF PYRIMIDINE ANALOGS AND THEIR NUCLEOSIDES [J].
DAHER, GC ;
HARRIS, BE ;
DIASIO, RB .
PHARMACOLOGY & THERAPEUTICS, 1990, 48 (02) :189-222
[52]  
Damjanov N, 2000, ONCOLOGY-NY, V14, P799
[53]  
Damle B, 2001, CLIN CANCER RES, V7, P517
[54]  
DANIELS M, 1993, JPN J CLIN ONCOL, V23, P363
[55]  
Danno M, 2001, Gan To Kagaku Ryoho, V28, P195
[56]   The oral fluorinated pyrimidines [J].
de Bono, JS ;
Twelves, CJ .
INVESTIGATIONAL NEW DRUGS, 2001, 19 (01) :41-59
[57]   Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer [J].
de la Torre, A ;
Ramos, S ;
Valcárcel, FJ ;
Candal, A ;
Regueiro, CA ;
Romero, J ;
Magallón, R ;
Salinas, J ;
de las Heras, M ;
Veiras, C ;
Tisaire, JL ;
Aragón, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (03) :629-634
[58]  
DECASTRO J, 2000, P AN M AM SOC CLIN, V19, pA1040
[59]  
DECASTRO J, 2001, P AN M AM SOC CLIN, V20, pA2310
[60]   Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT [J].
Del Vecchio, M ;
Procopio, G ;
Cassata, A ;
Pozzi, P ;
Busto, G ;
Celio, L ;
Bajetta, E .
TUMORI, 1999, 85 (01) :6-11